Skip to main content

Table 2 Mutational rate of most frequently altered genes in CRC in HM, HM-like and non-HM group

From: An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

Genes Pathway HM (%) HM-like (%) Non-HM (%) P value
APC WNT signaling 49 59 84 ***
AMER1 WNT signaling 27 15 9 ***
CTNNB1 WNT signaling 24 12 3 ***
TCF7L2 WNT signaling 24 0 7 ***
FBXW7 WNT signaling 40 32 11 ***
ARID1A WNT signaling 45 5 6 ***
SOX9 WNT signaling 15 27 11 *
TGFBR2 TGF-β signaling 12 7 1 NS
ACVR2A TGF-β signaling 37 15 1 **
SMAD4 TGF-β signaling 15 17 12 NS
PIK3CA PIK3 signaling 40 41 21 ***
PTEN PIK3 signaling 22 10 3 **
FAT4 Hippo signaling pathway 76 24 15 ***
ERBB2 MAPK signaling 15 5 2 ***
ERBB3 MAPK signaling 22 5 2 ***
KRAS MAPK signaling 26 59 41 ***
NRAS MAPK signaling 4 7 7 NS
BRAF MAPK signaling 62 12 3 ***
ATM DNA damage response 50 10 7 ***
TP53 DNA damage response 29 15 69 ***
LRP1B Membrane trafficking 53 5 13 ***
KMT2D Histone methyl transferase 64 15 3 ***